Mizuho Reaffirms Buy Rating for Supernus Pharmaceuticals (SUPN)

Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “buy” rating reissued by investment analysts at Mizuho in a report issued on Friday, TipRanks reports.

Other equities research analysts have also issued reports about the stock. Zacks Investment Research raised shares of Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a report on Wednesday, March 13th. Cantor Fitzgerald reaffirmed a “buy” rating and set a $57.00 price target on shares of Supernus Pharmaceuticals in a report on Wednesday, February 27th. B. Riley set a $65.00 price target on shares of Supernus Pharmaceuticals and gave the company a “buy” rating in a report on Monday, March 4th. BidaskClub lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 22nd. Finally, ValuEngine lowered shares of Supernus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, March 6th. Three analysts have rated the stock with a sell rating, one has given a hold rating and six have given a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $56.13.

SUPN stock traded down $0.34 during mid-day trading on Friday, hitting $33.25. The stock had a trading volume of 336,765 shares, compared to its average volume of 591,344. The company has a quick ratio of 2.59, a current ratio of 2.77 and a debt-to-equity ratio of 0.75. Supernus Pharmaceuticals has a 52 week low of $30.05 and a 52 week high of $61.25. The firm has a market cap of $1.74 billion, a P/E ratio of 16.22, a P/E/G ratio of 1.13 and a beta of 1.57.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $0.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.44 by ($0.10). The company had revenue of $85.50 million for the quarter, compared to the consensus estimate of $102.26 million. Supernus Pharmaceuticals had a net margin of 25.49% and a return on equity of 23.60%. The company’s revenue for the quarter was down 5.4% compared to the same quarter last year. During the same period last year, the firm posted $0.49 earnings per share. Equities analysts predict that Supernus Pharmaceuticals will post 2.24 EPS for the current year.

In related news, CFO Gregory S. Patrick sold 20,000 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Wednesday, February 27th. The shares were sold at an average price of $41.53, for a total transaction of $830,600.00. Following the sale, the chief financial officer now directly owns 67,896 shares of the company’s stock, valued at approximately $2,819,720.88. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 6.20% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its position in Supernus Pharmaceuticals by 0.9% during the 4th quarter. BlackRock Inc. now owns 8,075,659 shares of the specialty pharmaceutical company’s stock worth $268,272,000 after buying an additional 72,658 shares during the period. Dimensional Fund Advisors LP boosted its position in Supernus Pharmaceuticals by 4.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,378,566 shares of the specialty pharmaceutical company’s stock worth $48,304,000 after buying an additional 64,805 shares during the period. Rice Hall James & Associates LLC boosted its position in Supernus Pharmaceuticals by 9.5% during the 1st quarter. Rice Hall James & Associates LLC now owns 1,000,381 shares of the specialty pharmaceutical company’s stock worth $35,053,000 after buying an additional 86,645 shares during the period. Macquarie Group Ltd. boosted its position in Supernus Pharmaceuticals by 33.1% during the 1st quarter. Macquarie Group Ltd. now owns 994,155 shares of the specialty pharmaceutical company’s stock worth $34,835,000 after buying an additional 247,111 shares during the period. Finally, Fiera Capital Corp boosted its position in Supernus Pharmaceuticals by 6.0% during the 4th quarter. Fiera Capital Corp now owns 941,530 shares of the specialty pharmaceutical company’s stock worth $31,277,000 after buying an additional 53,404 shares during the period. Institutional investors and hedge funds own 98.62% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.

See Also: Exchange-Traded Funds (ETFs)

Analyst Recommendations for Supernus Pharmaceuticals (NASDAQ:SUPN)

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply